Heart Transplant Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The heart transplant market size has grown rapidly in recent years. It will grow from $11.49 billion in 2024 to $12.66 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to medical advancements, increased awareness and education, advancements in organ preservation, healthcare infrastructure.

The heart transplant market size is expected to see strong growth in the next few years. It will grow to $18.1 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to government support and funding, globalization of transplant programs, increasing transplant center capacity, integration of telemedicine and remote monitoring. Major trends in the forecast period include technological advancements, artificial heart and assist devices, artificial intelligence (AI) in donor organ selection.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the heart transplant market in the coming years. Cardiovascular diseases encompass a range of conditions that affect the heart and blood vessels. A heart transplant is a treatment of last resort for individuals with end-stage heart failure who have not responded to other therapies. It significantly improves the quality of life and extends life expectancy. For example, in September 2024, the British Heart Foundation, a UK-based cardiovascular research charity, reported that approximately 7.6 million people in the UK are currently affected by heart and circulatory diseases, including 4 million men and 3.6 million women. This number is expected to increase by 1 million by 2030 and could rise by an additional 2 million by 2040. As a result, the growing prevalence of cardiovascular diseases will drive the heart transplant market.

The heart transplant market is experiencing growth driven by an increased awareness of organ donation and transplantation. This awareness encompasses knowledge, understanding, and community consciousness regarding the processes, significance, and impact of these procedures in healthcare. This heightened awareness is playing a substantial role in the realm of heart transplants, leading to an expanded donor pool, reduced waiting times for recipients, and improved patient outcomes. For instance, in January 2023, the United Network for Organ Sharing, a US-based non-profit organization focused on science and education, reported a record of 42,887 organ transplants in the US in 2022, marking a 3.7% increase from the previous year. This included 9,528 liver transplants, 4,111 heart transplants, and 2,692 lung transplants, underscoring the impact of this growing awareness. Consequently, the surge in awareness about organ donation and transplantation is a key driver for the heart transplant market.year. This included 9,528 liver transplants, 4,111 heart transplants, and 2,692 lung transplant. Therefore, the growing awareness about organ donation and transplantation will drive the heart transplant market.

Major companies in the heart transplant market are increasingly focused on developing innovative solutions, such as heart preservation technology, to enhance patient outcomes and improve transplant success rates. This technology significantly extends the preservation time of the heart outside the body compared to traditional ice storage, leading to better outcomes and reduced complications after transplantation. For instance, in May 2023, Xvivo Perfusion AB, a Sweden-based medical technology company, received approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption (IDE) application for heart preservation technology. This approval enabled the company to launch the "PRESERVE Clinical Trial," a prospective, multicenter, single-arm, open-label study focused on evaluating hearts transplanted after non-ischemic heart preservation from extended donors, including those from Donation after Circulatory Death (DCD). The key feature of Xvivo's heart preservation technology is its non-ischemic hypothermic perfusion system, which uses cold, oxygenated perfusion to preserve donor hearts during transport.

In August 2024, Getinge, a Sweden-based company specializing in medical technology and healthcare solutions, acquired Paragonix Technologies for an undisclosed amount. This acquisition allows Getinge to strengthen its capabilities in organ preservation and transportation, with a focus on improving patient outcomes in transplant procedures. Paragonix Technologies, a U.S.-based company, designs, manufactures, and sells devices used for the transport of organs for transplant.

Major companies operating in the heart transplant market are Optum Inc., Novartis Pharmaceuticals UK Ltd., Abbott Laboratories, Medtronic PLC, Stryker Corporation, Roche Diagnostics Ltd., Mayo Clinic, Cleveland Clinic, AstraZeneca PLC, Massachusetts General Hospital, Terumo Corp., NewYork-Presbyterian Hospital, Cedars-Sinai Medical Center, Maquet Holding B.V. and Co. KG., Teleflex Inc., Stanford Health Care, Johns Hopkins Hospital, Thoratec Corporation, Abiomed Inc., Baylor St. Lukes Medical Center, Transonic Systems Inc., Berlin Heart GmbH, HeartWare International Inc., SynCardia Systems LLC., Carmat SA, BiVACOR Inc., Apaxis Medical Inc., Calon Cardio-Technology Ltd., CardiacAssist Inc., The Texas Heart Institute.

North America was the largest region in the heart transplant market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in heart transplant report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the heart transplant market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The heart transplant market includes revenues earned by entities by providing services such as patient evaluation and selection, waitlist management, donor heart procurement, transplant surgery, immunosuppression management, psychosocial support and complications management services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

A heart transplant is a sophisticated surgical procedure in which a damaged or diseased heart is removed and replaced with a healthy donor heart. This intervention is crucial and can be life-saving for individuals suffering from end-stage heart failure or specific severe heart conditions.

There are several types of heart transplant surgeries, including total artificial heart, biventricular pacing, ventricular assist devices, and other specialized procedures. A total artificial heart is a mechanical device specifically engineered to take over the functions of both the left and right ventricles of the natural human heart. This category encompasses various transplant techniques like autografts, allografts, and others. The primary recipients of these procedures are hospitals, cardiac institutes, and other specialized medical facilities.

The heart transplant market research report is one of a series of new reports that provides heart transplant market statistics, including heart transplant industry global market size, regional shares, competitors with a heart transplant market share, detailed heart transplant market segments, market trends and opportunities and any further data you may need to thrive in the heart transplant industry. This heart transplant market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.